Wearable-Supported Prehabilitation and Rehabilitation for Patients Undergoing Surgery for Pancreatic Cancer

Sponsor
Manchester University NHS Foundation Trust
Study ID
NCT07772258
Status
Not Yet Recruiting

Notify me when recruiting opens

Save your spot on the interest list for this study. We'll keep your details with this study so our team can follow up when recruiting opens.

Not yet recruiting

Add your contact details and location so we can keep your interest tied to this study.

Conditions

  • Pancreatic Cancer
  • Pancreatic Neoplasms
  • Pancreatic Surgery
  • Periampullary Carcinoma
  • Perioperative Care

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Corsano CardioWatch — DEVICE
    A wearable monitoring device used throughout the perioperative pathway to collect continuous physiological and activity data, including measures such as physical activity, heart rate, respiratory rate, oxygen saturation, skin temperature, and sleep-related metrics.
  • Prehab4Cancer Programme — BEHAVIORAL
    A personalised prehabilitation and rehabilitation programme comprising exercise, nutritional support, and wellbeing support delivered before and after pancreatic surgery.

Study Details

The goal of this clinical trial is to evaluate whether a wearable-enabled prehabilitation and rehabilitation pathway can improve recovery and post-operative outcomes in adults undergoing surgery for pancreatic cancer or related pancreatic/periampullary conditions. The main questions it aims to answer are: Does a wearable-enabled prehabilitation and rehabilitation programme reduce post-operative complications within 30 and 90 days after surgery? Is the use of wearable devices and remote monitoring feasible, acceptable, and useful for patients and healthcare professionals during the perioperative pathway? Researchers will compare patients receiving the wearable-enabled pathway with a matched historical control group who received standard care to determine whether the intervention is associated with improved surgical and recovery outcomes. Participants will: Provide informed consent and complete baseline assessments and questionnaires. Take part in the Greater Manchester Prehab4Cancer programme before surgery, including personalised exercise, nutritional support, and wellbeing support. Wear a Corsano CardioWatch device to continuously monitor physiological and activity data. Use home monitoring equipment, including weight scales and blood pressure monitoring devices. Complete questionnaires and participant logs during prehabilitation and recovery. Receive regular support from the research team during participation. Undergo pancreatic surgery and receive standard NHS perioperative care. Continue wearable monitoring and rehabilitation after hospital discharge. Be followed for up to 12 months after surgery using routine clinical data to assess recovery, complications, hospital utilisation, and survival. Optionally participate in a focus group to discuss their experiences of wearable-enabled care.

Key Dates

First listed
Aug 19, 2026
Start date
Oct 1, 2026
Status verified
Aug 2026
Primary completion
Mar 31, 2028
Completion
Sep 30, 2028

Study Design

Enrollment
120 participants (estimated)
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: Wearable-Enabled Prehabilitation and Rehabilitation
    Participants undergoing pancreatic surgery will receive the Greater Manchester Prehab4Cancer programme supported by wearable monitoring, home physiological monitoring, and remote follow-up throughout the perioperative pathway. Outcomes will be compared with a propensity-score-matched historical cohort identified from routine electronic health records.
  • No Intervention: Matched Historical Standard Care Cohort
    Historical patients who underwent pancreatic surgery and received standard perioperative care without wearable monitoring. Participants will be identified retrospectively from electronic health records and matched to intervention participants using propensity score methods based on demographic and clinical characteristics. No study intervention will be delivered.

Primary Outcome Measure

Post-operative complications [ Time Frame: 30 and 90 days post-surgery ]

Central Contacts

Find similar trials

Nationwide
Pancreatic cancer trialsOncology trialsGI oncology trials

Related Studies